Skip to main content

Table 2 The concentration of carboplatin in plasma by LC-MS (left) and in xenograft tissues and patient PBMCs by ICP-MS (bottom)

From: Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors

  Tissue Amount of tissue
median (RSE)
Comparison Method Subjects (N) Tissues (N) Tissues (N)
<LOD; <LOQ
Median conc.
(RSE %)a
P
b) Carboplatin Plasma 50 μL 0.6 h LC-MS 15 15 0; 0 24 (20)  
    5 h 15 15 15; 15 <0.01  
Carboplatin adducts TNBC xenograft tissue 12 μm sections:
1.9 μg DNA (56%)
All ICP-MS 13 13   0.55 (30%)  
HCC70 5 5   1.85 (42%) 0.091(Cell source)
MDA-MB-231 3 3   0.55 (23%)
MDA-MB-436 5 5   0.54 (27%)
Placebo 5 5   0.476 (57) 0.087 (V yes/no)
Veliparib 60mg/kg 8 8   0.977 (33) 0.083(Cell source + V)
  PBMCs from patients Derived from 5–15 mL blood, extracted from a median of 2,160,000 cells 51 51   0.0552 (30%)  
  1. MALDI matrix-assisted laser desorption/ionization, TBNC triple negative breast cancer, PBMC peripheral blood mononuclear cells, RSE relative standard errors, ROI region of interest, V veliparib
  2. aConcentration (Conc.) of veliparib and carboplatin in mg/L, carboplatin adducts in μmol/g DNA
  3. *P value adjusted for dose